Tuberculosis has a last-mile delivery problem in Africa. A new logistics platform is trying to fix it.

Tuberculosis remains Africa's most overlooked investment thesis. While global attention fixates on pandemic preparedness, TB quietly kills more people annually than any other infectious disease—10.7 million cases in 2024 alone, with Africa bearing a disproportionate burden. Yet the paradox is stark: the disease is curable. The real killer isn't the bacterium; it's the last mile.

Across sub-Saharan Africa, treatment failure rates soar not because medicine is ineffective, but because patients cannot reliably access it. A patient diagnosed in rural Uganda must navigate fragmented supply chains, unreliable cold chains, and opaque inventory systems to obtain a six-month drug regimen. Many never complete treatment. This inefficiency doesn't just claim lives—it costs the continent an estimated $16 billion annually in lost productivity and healthcare expenditure, according to African Development Bank analysis.

The infrastructure gap is specific and quantifiable. Most African TB programs rely on paper-based inventory systems, manual reporting, and delivery networks designed in the 1990s. Drug stockouts occur randomly; excess inventory sits elsewhere. Distribution bottlenecks compound: a anti-TB medication might reach a national warehouse but stall for weeks before reaching district clinics, especially in fragile or conflict-affected states. Cold-chain breakdowns render temperature-sensitive drug formulations useless. Patient adherence collapses when drugs are unavailable at scheduled treatment intervals.

This is where logistics platforms targeting healthcare supply chains represent a genuine market opportunity for European entrepreneurs and venture capital. A new generation of African logistics startups—leveraging real-time GPS tracking, blockchain-enabled inventory verification, and AI-powered demand forecasting—are digitizing TB drug distribution. These platforms aggregate fragmented local courier networks, integrate with hospital management systems, and provide visibility across the entire supply chain. For TB specifically, the market is nascent but critical: national TB programs across 30+ African countries represent a collective addressable market of approximately $2.2 billion annually in distribution, monitoring, and logistics services.

European investors should note several advantages. First, TB supply chain solutions address a structural, recurring need—not a one-off procurement problem. Second, the customer base is stable: government health ministries and WHO-supported programs have committed funding. Third, regulatory barriers are lower than in pharmaceutical manufacturing; these are tech-enabled logistics plays, not medical devices. Fourth, the problem is identical across countries, enabling rapid geographic scaling without major product iteration.

The investment thesis rests on three pillars: (1) demonstrated unit economics—successful pilots in Kenya, Nigeria, and South Africa show 30-40% reduction in stockouts and 25% faster delivery cycles; (2) policy tailwinds—the WHO and African Union have prioritized TB supply chain strengthening, creating procurement pathways; and (3) complementary revenue streams—platforms initially focused on TB can expand to malaria, HIV, and routine vaccines, creating 4-5x TAM expansion within three years.

Risk factors are real: government payment delays, political instability in high-burden countries, and competition from established medical logistics firms. But for investors comfortable with 5-7 year horizons and development-impact alignment, TB logistics represents a rare intersection of compelling social need, addressable market size, and venture-scale returns.

---